Interleukin 15 mediates joint destruction in staphylococcus aureus arthritis

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 687-696

  Henningsson, Louise ^a   Jirholt, Pernilla ^a   Bogestål, Yalda Rahpeymai ^a   Eneljung, Tove ^a   Adiels, Martin ^b   Lindholm, Catharina ^a   McInnes, Iain ^c   Bulfone Paus, Silvia ^d,e   Lerner, Ulf H ^a,f   Gjertsson, Inger ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Research Center Borstel   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 15 ANTIBODY; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CLEARANCE; BACTERIAL LOAD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOLOGY; JOINT DESTRUCTION; KIDNEY; KNOCKOUT MOUSE; MALE; MORBIDITY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS ARTHRITIS; SYNOVITIS; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ARTHRITIS, INFECTIOUS; FEMALE; GENE KNOCKOUT TECHNIQUES; HISTOCYTOCHEMISTRY; INTERLEUKIN-15; JOINTS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOCLASTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84864961259     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis295     Document Type: Article

References (43)

1. Tarkowski A. Infection and musculoskeletal conditions: Infectious arthritis. Best Pract Res Clin Rheumatol 2006; 20:1029-44.
2. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965-8. (Pubitemid 24196167)
3. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601. (Pubitemid 44134092)
4. Orinska Z, Maurer M, Mirghomizadeh F, et al. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med 2007; 13:927-34. (Pubitemid 47222042)
5. Tagaya Y, Kurys G, Thies TA, et al. Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci USA 1997; 94:14444-9. (Pubitemid 28041393)
6. Gaggero A, Azzarone B, Andrei C, et al. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur J Immunol 1999; 29:1265-74. (Pubitemid 29164173)
7. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-9. (Pubitemid 28264750)
8. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97:14-32. (Pubitemid 32061238)
9. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2009; 184:1401-9.
10. Zheng X, Wang Y, Wei H, Ling B, Sun R, Tian Z. Bcl-xL is associated with the anti-apoptotic effect of IL-15 on the survival of CD56(dim) natural killer cells. Mol Immunol 2008; 45:2559-69.
11. Bulfone-Paus S, Ungureanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997; 3:1124-8. (Pubitemid 27444454)
12. Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997; 90:2804-9. (Pubitemid 27413491)
13. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J Clin Invest 1998; 101:1261-72. (Pubitemid 28145242)
14. Thurkow EW, van der Heijden IM, Breedveld FC, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997; 181:444-50. (Pubitemid 27223532)
15. McInnes IB, Gracie JA, Harnett M, Harnett W, Liew FY. New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis 2003; 62 (Suppl 2):ii51-4.
16. McInnes IB, al-Mughales J, Field M, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2:175-82. (Pubitemid 26057554)
17. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Soluble IL-15 receptor alpha-chain administration prevents murine collageninduced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998; 160:5654-60. (Pubitemid 28267861)
18. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52:2686-92. (Pubitemid 41369096)
19. Gabay C, McInnes IB. The biological and clinical importance of the "new generation" cytokines in rheumatic diseases. Arthritis Res Ther 2009; 11:230.
20. Ogata Y, Kukita A, Kukita T, et al. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 1999; 162:2754-60. (Pubitemid 29309299)
21. Djaafar S, Pierroz DD, Chicheportiche R, Zheng XX, Ferrari SL, Ferrari-Lacraz S. Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum 2010; 62:3300-10.
22. Bremell T, Lange S, Svensson L, et al. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum 1990; 33:1739-44.
23. Bremell T, Abdelnour A, Tarkowski A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun 1992; 60:2976-85.
24. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-80.
25. Camplejohn KL, Allard SA. Limitations of safranin 'O' staining in proteoglycan-depleted cartilage demonstrated with monoclonal antibodies. Histochemistry 1988; 89:185-8.
26. Zenger S, Hollberg K, Ljusberg J, et al. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 2007; 41:820-32. (Pubitemid 47576835)
27. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-76. (Pubitemid 28557595)
28. Nilsson N, Bremell T, Tarkowski A, Carlsten H. Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 1999; 117:63-9. (Pubitemid 29292779)
29. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
30. Soderstrom K, Stein E, Colmenero P, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci USA 2010; 107:13028-33.
31. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-99. (Pubitemid 33062512)
32. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152:943-51. (Pubitemid 28173356)
33. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A. Experimental Staphylococcus aureus arthritis in mice. Infect Immun 1991; 59:2615-23.
34. Nilsson IM, Bremell T, Ryden C, Cheung AL, Tarkowski A. Role of the staphylococcal accessory gene regulator (sar) in septic arthritis. Infect Immun 1996; 64:4438-43. (Pubitemid 26357041)
35. Zhou Q, Gu CQ, Hu XY, et al. Role of interleukin-6 in the pathogenesis of an avian model of Staphylococcus aureus arthritis. Poult Sci 2007; 86:1245-50. (Pubitemid 47581003)
36. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13:1189-96. (Pubitemid 24074725)
37. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257:88-91.
38. Wong GG, Witek-Giannotti JS, Temple PA, et al. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol 1988; 140:3040-4.
39. Kurihara N, Civin C, Roodman GD. Osteotropic factor responsiveness of highly purified populations of early and late precursors for human multinucleated cells expressing the osteoclast phenotype. J Bone Miner Res 1991; 6:257-61.
40. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993; 90:11924-8. (Pubitemid 24008752)
41. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signaling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-? and IL-17. Rheumatology 2008; 47:1635-40.
42. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002; 169:3353-62. (Pubitemid 35013185)
43. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010; 6:843-54.